Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the target of a significant drop in short interest in June. As of June 30th, there was short interest totaling 4,485 shares, a drop of 43.2% from the June 15th total of 7,902 shares. Based on an average daily volume of 4,538 shares, the short-interest ratio is presently 1.0 days.
Oculis Trading Up 0.4%
NASDAQ:OCSAW traded up $0.02 on Friday, hitting $4.59. 5,346 shares of the company’s stock were exchanged, compared to its average volume of 6,024. The firm has a 50-day moving average price of $8.98 and a 200-day moving average price of $13.03. Oculis has a 52 week low of $3.63 and a 52 week high of $22.64.
About Oculis
Oculis SA is a clinical?stage biopharmaceutical company focused on developing disease?modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small?molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
See Also
- Five stocks we like better than Oculis
- Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop
- Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs?
- The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story
- Why Intuitive Surgical’s Strong Quarter Still Spooked Investors
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
